提高和维持儿科 B 细胞急性淋巴细胞白血病嵌合抗原受体 T 细胞治疗的疗效。
Improving and Maintaining Responses in Pediatric B-Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptor-T Cell Therapy.
机构信息
From the Department of Pediatrics, Division of Oncology, The Children's Hospital of Philadelphia.
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
出版信息
Cancer J. 2021;27(2):151-158. doi: 10.1097/PPO.0000000000000513.
Chimeric antigen receptor T therapy has heralded a new era in the treatment of acute lymphoblastic leukemia (ALL) and other hematologic malignancies. In this autologous immunotherapy, patient-derived T cells are genetically engineered and then infused back to kill the leukemia cells. The observed response rates in ALL are a testament to the success of this therapy. However, there have been instances where the patients either did not respond or relapsed after initial response. Emergence of resistance due to antigen loss and T-cell exhaustion has been observed. This poses a challenge in making this therapy successful for every ALL patient and warrants deeper understanding of emergence of resistance and potential approaches to overcome them. Here we discuss current perspectives and advances in this area.
嵌合抗原受体 T 细胞疗法开创了治疗急性淋巴细胞白血病（ALL）和其他血液系统恶性肿瘤的新纪元。在这种自体免疫疗法中，患者来源的 T 细胞经过基因工程改造，然后回输以杀死白血病细胞。ALL 观察到的反应率证明了这种疗法的成功。然而，有些患者既没有反应，也没有在初始反应后复发。由于抗原丢失和 T 细胞耗竭而出现耐药的情况已经被观察到。这给使每个 ALL 患者都能成功接受这种治疗带来了挑战，因此需要更深入地了解耐药的出现以及克服耐药的潜在方法。在这里，我们讨论了这一领域的最新观点和进展。
Zotero 插件